Health Condition 1: C710- Malignant neoplasm of cerebrum, except lobes and ventricles
Conditions
Interventions
Intervention1: Amisulpride: Injection amisulpride 4mg is given at the end of the surgery to prevent post operative nausea and vomiting. Monitored for first 24 hours.
Control Intervention1: Injection o
Sponsors
Academic session Sree Chitra Thirunal Institute of Science and Technology
Eligibility
Inclusion criteria
Inclusion criteria: 1) Adult patients undergoing supratentorial craniotomy for tumour.
Exclusion criteria
Exclusion criteria: 1)Patient refusal 2)Patients with history of drug or alcohol abuse 3)History of nausea or vomiting 4)Pregnant or lactating women 5)Chemotherapy or radiation therapy during the previous 1month 6)Planned for postoperative ventilation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the effectiveness of amisulpride vs ondansetron in prevention of post operative nausea and vomiting during the first 24 hours in patients undergoing craniotomy for supratentorial tumor.Timepoint: 1 year for the recruitment 1 month for data analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the severity of nausea, use of rescue medications, postoperative pain and analgesic requirement, and incidences of adverse events in the first 24 hours postoperatively, in patients receiving amisulpride and ondansetron who are undergoing craniotomy for supratentorial tumor.Timepoint: 1 year for the recruitment 1 month for data analysis | — |
Countries
India
Contacts
Public ContactSreeja R
Sree Chitra Thirunal Institute of Medical Sciences and Technology
Outcome results
None listed